<<There will not be 15% mortality in the placebo group, forget that.
If there is then Xoma should patent the placebo and forget about Bpi.>>
Great idea, Cacaito. How about a Xoma subsidiary or tracking stock, say, Placebo-dot-com? (Symbol: INRT)
We could issue an IPO at $30 a share, start a double-blind study measuring a new investigative compound which we will name Nostrum®©™, against a naturally occurring substance produced by the human body, say, spit, which has been chemically altered with, umm, ahh, Doublemint gum. Of course, we first issue 46 breathless press releases about new patents, then telephone the saps who bought the IPO and ask how many shares they own while we privately place the shares we retained for ourselves with some offshore investors. Once that's over, we pack up and move to Bermuda, then go short before the P-3 results are released.
Trouble with is, reaching the number of patient deaths required by the FDA could take awhile. |
